Nautilus reports oncology assay gains as Q3 loss grows to $15.6M
Nautilus cited progress in its platform and oncology assays in Q3, but its net loss grew to $15.6 million, according to TradingView.
- published on Newsmetry
- original source published
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner. connect the api →
what happened
According to TradingView, Nautilus made encouraging strides in its platform and oncology assay work during the third quarter, though its year-over-year net loss rose to $15.6 million.
Cash, cash equivalents and investments came to $114.3 million. The company still plans to make its instrument available in mid-2027.
why it matters
For NAUT investors, the key points are the trajectory of losses, the size of the cash reserve and the timing of instrument availability. A bigger loss paired with a sizable liquidity buffer suggests the company is still funding development from existing capital. The story concerns a single company and has limited relevance for the broader market.
tags
instruments
sources
- NAUT: Oncology assay progress advanced as Q3 net loss widened to $15.6M — TradingView, 27 October 2026 at 10:05 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
the public page opens no earlier than 15 minutes after we detect the story. approved stories may reach the api sooner.
get stories in real time ↗